Morgan Stanley Maintains Overweight on Eli Lilly, Raises Price Target to $1430

Morgan Stanley analyst Terence Flynn has maintained an Overweight rating on Eli Lilly (NYSE: LLY) and increased the price target from $1419 to $1430. This adjustment reflects positive sentiment towards the company's performance and future prospects.